HDAC9 and neoplasm: Aberrant expression or recruitment to specific loci of HDACs has been identified in various types of cancers, and HDAC inhibitors have been shown to have anti-tumor activities, especially in hematologic cancers such as cutaneous T-cell lymphoma and myelodysplastic syndromes86.